RDC 5
Alternative Names: Chroneuro™; RDC5Latest Information Update: 28 Jul 2026
At a glance
- Originator Chronos Therapeutics
- Developer TheraCryf
- Class Neuroprotectants; Osteoporosis therapies
- Mechanism of Action Autophagy stimulants; Reactive oxygen species modulators; Synuclein inhibitors; Tau protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Neurodegenerative disorders; Obesity
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Neurodegenerative disorders
- Discontinued Obesity; Osteoporosis; Postmenopausal osteoporosis
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis in United Kingdom (PO)
- 27 Jun 2023 Phase-I clinical trials in Amyotrophic lateral sclerosis in United Kingdom (PO) (Chronos Therapeutics pipeline, March 2023)
- 27 Mar 2023 Discontinued - Preclinical for Obesity in United Kingdom (PO)